Abstract
Background: Inadequate Thyroid Hormone at birth in newborns is known as Congenital Hypothyroidism (CH) and it has a critical role in their growth and brain development. As a result, untreated CH and abnormal GH/IGF1 levels can lead to failure to thrive, osteoporosis, and Diabetic Retinopathies, among other problems. This retrospective study examines the chances of developing growthhormone disruption and Diabetes Mellitus in patients diagnosed with Congenital Hypothyroidism at the Security Forces Hospital in Riyadh, Saudi Arabia.
Methodology: A retrospective chart review of growth hormone deficient (GHD) patients was done at the security force hospital in Riyadh, Saudi Arabia. The data was collected from the medical records of the patients. The study included all patients with growth hormone deficiency (GHD) who had complete clinical, diagnostic and treatment data.
Result: At the beginning of the research, 287 growth hormone-deficient (GHD) children ranging in age from 1 to 15 years old were evaluated for diabetes. A total of 151 (52.6%) of the 287 patients gotlevothy-roxine therapy, while the remaining 136 (47.4%) did not (control group). Because the p-value <0.05 (t(149) = 1.165, p = 0.246), the mean difference in blood sugar level changes is not statistically significant (t(149) = 1.165, p = 0.246).
Conclusion: We found that levothyroxine therapy has no discernible effect on blood sugar level fluctuations in males and females.